Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Belly muscle size may predict surgery risks in cancer patients

NCT ID NCT07098871

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 129 adults with gastrointestinal cancer to see if measuring the thickness of their belly and diaphragm muscles before surgery could help predict complications after the operation. Researchers used ultrasound to measure these muscles and then tracked recovery for 30 days. The goal was to find simple, non-invasive ways to identify patients at higher risk, so doctors can better prepare and personalize care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

129 people

The number who actually took part.

Started

Sep 2025

Finished

Mar 2026

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with operable gastrointestinal system cancer from tertiary cancer center

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age over 18 years * Patients scheduled for laparoscopic or open surgery due to GIS malignancy between 01.05.2025 and 01.11.2025 * Postoperative follow-up at our center for a minimum of 30 days Exclusion Criteria: * Age under 18 years * Patients not undergoing surgery * Patients undergoing surgery for indications other than GIS malignancy * Patients with follow-up data shorter than 30 days

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Complication are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ankara Oncology Training and Research Hospital

    Ankara, 06200, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.